🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

👏This state-of-the-art review from #isth2023 summarizes the role of #platelets in ischemic #stroke, as example of thrombo-inflammation, and cerebral venous #thrombosis, which is an immunothrombotic disease. Fantastic work from @stegnerlab! rpthjournal.org/article/S2475-…

The 3rd edition of the 4EU+PharmacoEpi course has just started with 22 students from 5 EU universities ! A new extended edition supporting an integrative educational 🇪🇺 program in pharmacoepidemiology in the 4EUplusAlliance

📰 Our review is online Thrombosis Research discussing risk factors during the acute phase of DVT that are associated with the development of PTS ⚡️🦵 👏Bravo Lina KHIDER ! Planquette David Smadja 🎗️🧡 Goudot Guillaume Sanchez Olivier Med-Vasculaire HEGP INNOVTE thrombosisresearch.com/article/S0049-…

3⃣rd edition of the 4EU+PharmacoEpi course with #PharmacoEpi students from all over Europe at Uni Heidelberg ! Great discussion on multi-database studies. Stay tuned for next edition in Jan 2025 ! 4EUplusAlliance sante.sorbonne-universite.fr/en/internation…

1/ Published today: The updated evidence-based recommendations for managing Lower Extremity PAD, originally outlined in the 2016 Guideline, now incorporate the latest research findings to assist clinicians. ✍🏽:Heather L Gornik 📖: Circulation

The multi societal #PAD guideline in print at long last… Amazing things can happen when specialties work together, review the evidence, and put the patient at the center. Hats off to a most collaborative writing committee. herbaronowMD DartmouthSurgicalHSR Schuyler Jones

Colchicine is the first anti-inflammatory drug approved for athero-CVD prevention #CONVINCE tested colchicine in ischemic stroke🧠 The results were presented at #ESOC2024 by Peter Kelly European Stroke Org ucd.ie/medicine/news/… The primary endpoint was negative. A🧵with some thoughts

Presented at #ERA24: FLOW trial: In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and death from any cause while slowing loss of kidney function. nej.md/44U3slP

Also wanted to add, here is the free share link for anyone who needs access: authors.elsevier.com/a/1j8O41UYwnAsd

Check out the commentary on our #VEXAS article in @BloodJournal

3 papers in NEJM published simultaneously with presentations by Christie Ballantyne and Bob Rosenson at the European Atherosclerosis Society Congress in Lyon France - documenting huge reductions in remnant cholesterol after siRNA inhibition of ApoC3 and ANGTPL3

I had such a great time at the #EASCongress! Thanks to the #EASYoungFellows programme I was able to gain so many new experiences and expand my network. Hope to see you all again soon and thanks to everyone who made it such a fabulous congress! #EASCongress2024 #MyEAS2024 #EAS

pubmed.ncbi.nlm.nih.gov/38806178/

I was very honored to provide my commentary for the @BloodJournal on the very nice paper about thrombosis and VEXAS by the fantastic Emma M. Groarke team !

🚨Anticoagulation for stroke prevention in AF and Treatment of VTE and Portal Vein Thrombosis in Cirrhosis: Guidance ISTH 👏Congrats Alexander Gatt Virginia Adam Cuker MD, MS Deborah Siegal Simon Stanworth @LaraNRoberts1 🙏Honored to have been a part of this sciencedirect.com/science/articl…

🦴 Giant cell arteritis & Clonal hematopoiesis (CH) —somatic mutations in HSCs 👥 55.1% of patients with GCA had CH 🔬 TET2 & JAK2 mutations in #GCA ➡️ Relapse & poor outcomes. 👉 Screening for CH may guide tailored therapies. 🔓rmdopen.bmj.com/content/10/4/e… Alexis F. Guédon